TY - JOUR
T1 - Covid-19 biomarkers and advanced sensing technologies for point-of-care (Poc) diagnosis
AU - Etienne, Ernst Emmanuel
AU - Nunna, Bharath Babu
AU - Talukder, Niladri
AU - Wang, Yudong
AU - Lee, Eon Soo
N1 - Funding Information:
Acknowledgments: The authors acknowledge the research support from the New Jersey Institute of Technology (NJIT) and the National Science Foundation (Grant ID: NSF IIP-1643861). This research was carried out in part at the Center for Functional Nanomaterials, Brookhaven National Laboratory, which is supported by the U.S. Department of Energy, Office of Basic Energy Sciences, under Contract No. DE-SC0012704.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7
Y1 - 2021/7
N2 - COVID-19, also known as SARS-CoV-2 is a novel, respiratory virus currently plaguing humanity. Genetically, at its core, it is a single-strand positive-sense RNA virus. It is a beta-type Coronavirus and is distinct in its structure and binding mechanism compared to other types of coronaviruses. Testing for the virus remains a challenge due to the small market available for at-home detection. Currently, there are three main types of tests for biomarker detection: viral, antigen and antibody. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) remains the gold standard for viral testing. However, the lack of quantitative detection and turnaround time for results are drawbacks. This manuscript focuses on recent advances in COVID-19 detection that have lower limits of detection and faster response times than RT-PCR testing. The advancements in sensing platforms have amplified the detection levels and provided real-time results for SARS-CoV-2 spike protein detection with limits as low as 1 fg/mL in the Graphene Field Effect Transistor (FET) sensor. Additionally, using multiple biomarkers, detection levels can achieve a specificity and sensitivity level comparable to that of PCR testing. Proper biomarker selection coupled with nano sensing detection platforms are key in the widespread use of Point of Care (POC) diagnosis in COVID-19 detection.
AB - COVID-19, also known as SARS-CoV-2 is a novel, respiratory virus currently plaguing humanity. Genetically, at its core, it is a single-strand positive-sense RNA virus. It is a beta-type Coronavirus and is distinct in its structure and binding mechanism compared to other types of coronaviruses. Testing for the virus remains a challenge due to the small market available for at-home detection. Currently, there are three main types of tests for biomarker detection: viral, antigen and antibody. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) remains the gold standard for viral testing. However, the lack of quantitative detection and turnaround time for results are drawbacks. This manuscript focuses on recent advances in COVID-19 detection that have lower limits of detection and faster response times than RT-PCR testing. The advancements in sensing platforms have amplified the detection levels and provided real-time results for SARS-CoV-2 spike protein detection with limits as low as 1 fg/mL in the Graphene Field Effect Transistor (FET) sensor. Additionally, using multiple biomarkers, detection levels can achieve a specificity and sensitivity level comparable to that of PCR testing. Proper biomarker selection coupled with nano sensing detection platforms are key in the widespread use of Point of Care (POC) diagnosis in COVID-19 detection.
KW - Biomarker detection
KW - Biomarker sensing
KW - COVID-19 biomarkers
KW - COVID-19 sensing techniques
KW - Future diagnostic trends
UR - http://www.scopus.com/inward/record.url?scp=85111305554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111305554&partnerID=8YFLogxK
U2 - 10.3390/BIOENGINEERING8070098
DO - 10.3390/BIOENGINEERING8070098
M3 - Review article
AN - SCOPUS:85111305554
SN - 2306-5354
VL - 8
JO - Bioengineering
JF - Bioengineering
IS - 7
M1 - 98
ER -